AIM ImmunoTech (AIM)
(Real Time Quote from BATS)
$0.43 USD
+0.03 (6.23%)
Updated May 6, 2024 01:44 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
AIM 0.43 +0.03(6.23%)
Will AIM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AIM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for AIM
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
Aimia Inc. Announces Upcoming Q1 2024 Results
AIM ImmunoTech completes cGMP manufacturing of clinical vials of Ampligen
Energy Fuels Announces Q1-2024 Results, Including Continued Net Income, Continued Successful Uranium Ramp-Up, Commissioning Rare Earth Oxides Production, and Steps to Secure World-Scale Sources of Heavy Mineral Sands and Monazite
Analysts Offer Insights on Healthcare Companies: AIM ImmunoTech (AIM) and Avid Bioservices (CDMO)